Neuromuscular diseases

Neuromuscular diseases, affecting the nerves and muscles, lead to progressive muscle weakness and other debilitating symptoms. We are dedicated to advancing Neuromuscular disease treatment with rigorous scientific integrity and patient care.

By collaborating with leading experts and utilizing state-of-the-art technology, we aim to bring new hope to individuals and families affected by these challenging conditions.

Among these, Amyotrophic Lateral Sclerosis (ALS) is particularly severe. Our clinical research facility specializes in ALS, conducting advanced clinical trials to discover new therapies and improve patient outcomes.

Meet our scientific leader for ALS clinical trials

Our scientific leader in ALS is Prof. dr. Leonard van den Berg, professor of neurology at the University Medical Centre (UMC) Utrecht and director of ALS Centrum Nederland (the Dutch ALS Centre). He has vast experience in global ALS trials, established the prominent ALS site network TRICALS, and chairs the European Network to Cure ALS.

Brain Clinical is our proprietary network for CNS studies, providing highly experienced researchers for CNS clinical trials.

We are proud to partner with TRICALS, the largest European research initiative to find a cure and effective treatments for ALS. Our partnership with TRICALS provides innovative trial design and oversight capabilities combined with seasoned operational efficiency. With their help, we provide excellent patient recruitment and retention to support optimal execution for your ALS study.

Read more

Whether your project is a Phase I– III clinical trial, an investigator-initiated trial, an observational study or includes Real World Data; we have many years of experience in clinical trials in the field of ALS and provide you with a tailor-made solution that suits your needs.

Phase II European


175 patients | 8 countries | 25 sites

A Phase II, Multicenter, Randomized, Double-Blind Study Evaluating Safety and Efficacy in Patients with Amyotrophic Lateral Sclerosis

Phase III Global


600 patients | 12 countries | 75 sites

Multicenter trial for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis

Phase III European


300 patients | 9 countries | 31 sites

A multicenter study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis.

Julius Clinical’s expert ALS team

With our broad expertise gained through years of managing ALS clinical trials, Julius Clinical has the right people to give clients the best possible trial experience. Our in-house experts have skills and devotion that make a difference in ALS studies.

Lieza exalto

Related webinars

Webinar: Real-World Data in ALS

On 30 May, we hosted the webinar "Real-World Data in ALS", in which we explored the innovative integration of Real World Data (RWD) in clinical trials for Amyotrophic Lateral Sclerosis (ALS). As a critical step forward in the pursuit of effective ...

ALS resources

Explore our ALS trial capabilities, case studies, and other resources.


"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.


Twitter Facebook LinkedIn